VEGFA and neoplasm: A series of tumour angiogenesis inhibitors [such as Bevacizumab (Avastin®), Sorafenib (Nexavar®), and Sunitinib (Sutent®)] have been approved for clinical application by the Food and Drug Administration (FDA)4, and nearly all of these agents are directed against the VEGF-A/VEGFR2 signalling pathway.